Redox control of teratogenesis

Reproductive Toxicology

Volumn 35, Issue 1, 2013, Pages 165-179

  Hansen, Jason M ^a,b   Harris, Craig ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Cystic Fibrosis Research   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Embryo; Glutathione; Oxidative stress; Reactive oxygen species; Redox; Signaling; Teratogenesis; Thioredoxin

Indexed keywords

ACETYLCYSTEINE; ALCOHOL; ALPHA TOCOPHEROL; COCAINE; EPIDERMAL GROWTH FACTOR; GLUCOSE; GLUTATHIONE; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANNITOL; METHYLMERCURY; PHENYTOIN; REACTIVE OXYGEN METABOLITE; S ADENOSYLMETHIONINE; SUPEROXIDE DISMUTASE; TERATOGENIC AGENT; THALIDOMIDE; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

BONE DEFECT; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLEFT LIP PALATE; DEVELOPMENTAL STAGE; DIABETIC EMBRYOPATHY; DRUG MECHANISM; EMBRYOPATHY; FACE MALFORMATION; FETAL HYDANTOIN SYNDROME; HUMAN; MENTAL DEFICIENCY; MICROCEPHALY; MORNING SICKNESS; NAUSEA; NONHUMAN; ONTOGENY; ORGANOGENESIS; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PHOCOMELIA; PRENATAL DRUG EXPOSURE; REVIEW; SIGNAL TRANSDUCTION; TERATOGENESIS; TERATOGENICITY;

ANIMALS; GLUTATHIONE; HUMANS; ORGANOGENESIS; OXIDATION-REDUCTION; OXIDATIVE STRESS; TERATOGENS; THALIDOMIDE; THIOREDOXINS;

EID: 84871922476     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2012.09.004     Document Type: Review

References (130)

1. Schardein J. Chemically induced birth defects 2000, Marcel Dekker, Inc., Newy York, NY.
2. Marden P.M., Smith D.W., McDonald M.J. Congenital anomalies in the newborn infant, including minor variations, a study of 4,412 babies by surface examination for anomalies and buccal smear for sex chromatin. Journal of Pediatrics 1964, 64:357-371.
3. Petrini J., Damus K., Johnston R.B. An overview of infant mortality and birth defects in the United States. Teratology 1997, 56:8-10.
4. Karnofsky D.A. Drugs as teratogens in animals and man. Annual Review of Pharmacology 1965, 10:447-472.
5. Wilson J.G. Teratogenic effects of environmental chemicals. Federation Proceedings 1977, 36:1698-1703.
6. Dennery P.A. Effects of oxidative stress on embryonic development. Birth Defects Research C Embryo Today 2007, 81:155-162.
7. Fantel A.G. Reactive oxygen species in developmental toxicity: review and hypothesis. Teratology 1996, 53:196-217.
8. Fantel A.G., Person R.E. Involvement of mitochondria and other free radical sources in normal and abnormal fetal development. Annals of the New York Academy of Sciences 2002, 959:424-433.
9. Hansen J.M. Oxidative stress as a mechanism of teratogenesis. Birth Defects Research C Embryo Today 2006, 78:293-307.
10. Kovacic P., Somanathan R. Mechanism of teratogenesis: electron transfer, reactive oxygen species, and antioxidants. Birth Defects Research C Embryo Today 2006, 78:308-325.
11. Wells P.G., Kim P.M., Laposa R.R., Nicol C.J., Parman T., Winn L.M. Oxidative damage in chemical teratogenesis. Mutation Research 1997, 396:65-78.
12. Wells P.G., McCallum G.P., Chen C.S., Henderson J.T., Lee C.J., Perstin J., et al. Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicological Sciences 2009, 108:4-18.
13. Wilffert B., Altena J., Tijink L., van Gelder M.M., de Jong-van den Berg L.T. Pharmacogenetics of drug-induced birth defects: what is known so far?. Pharmacogenomics 2011, 12:547-558.
14. Abramson J.L., Hooper W.C., Jones D.P., Ashfaq S., Rhodes S.D., Weintraub W.S., et al. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 2005, 178:115-121.
15. Kaneto H., Katakami N., Kawamori D., Miyatsuka T., Sakamoto K., Matsuoka T.A., et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxidants & Redox Signaling 2007, 9:355-366.
16. Mena S., Ortega A., Estrela J.M. Oxidative stress in environmental-induced carcinogenesis. Mutation Research 2009, 674:36-44.
17. Weinbrenner T., Cladellas M., Isabel Covas M., Fito M., Tomas M., Senti M., et al. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis 2003, 168:99-106.
18. Sies H. Oxidative stress 1985, Acadmeic Press, London, UK.
19. Jones D.P., Mody V.C., Carlson J.L., Lynn M.J., Sternberg P. Redox analysis of human plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. Free Radical Biology and Medicine 2002, 33:1290-1300.
20. Nkabyo Y.S., Ziegler T.R., Gu L.H., Watson W.H., Jones D.P. Glutathione and thioredoxin redox during differentiation in human colon epithelial (Caco-2) cells. American Journal of Physiology-Gastrointestinal and Liver Physiology 2002, 283:G1352-G1359.
21. Hansen J.M., Zhang H., Jones D.P. Differential oxidation of thioredoxin-1, thioredoxin-2, and glutathione by metal ions. Free Radical Biology and Medicine 2006, 40:138-145.
22. Jones D.P. Redefining oxidative stress. Antioxidants Redox Signaling 2006, 8:1865-1879.
23. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radical Biology and Medicine 2001, 30:1191-1212.
24. Jones D.P., Go Y.M., Anderson C.L., Ziegler T.R., Kinkade J.M., Kirlin W.G. Cysteine/cystine couple is a newly recognized node in the circuitry for biologic redox signaling and control. FASEB Journal 2004, 18:1246-1248.
25. Droge W., Schulze-Osthoff K., Mihm S., Galter D., Schenk H., Eck H.P., et al. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB Journal 1994, 8:1131-1138.
26. Galter D., Mihm S., Droge W. Distinct effects of glutathione disulphide on the nuclear transcription factor kappa B and the activator protein-1. European Journal of Biochemistry 1994, 221:639-648.
27. Pineda-Molina E., Klatt P., Vazquez J., Marina A., Garcia de Lacoba M., Perez-Sala D., et al. Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry 2001, 40:14134-14142.
28. Harbison R.D. Chemical-biological reactions common to teratogenesis and mutagenesis. Environmental Health Perspectives 1978, 24:87-100.
29. Lum J.T., Wells P.G. Pharmacological studies on the potentiation of phenytoin teratogenicity by acetaminophen. Teratology 1986, 33:53-72.
30. Wong M., Wells P.G. Effects of N-acetylcysteine on fetal development and on phenytoin teratogenicity in mice. Teratogenesis Carcinogenesis Mutagenesis 1988, 8:65-79.
31. Wells P.G., Kupfer A., Lawson J.A., Harbison R.D. Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: evaluation of mephenytoin and its metabolite, nirvanol. Journal of Pharmacology and Experimental Therapeutics 1982, 221:228-234.
32. Teo S.K. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS Journal 2005, 7:E14-E19.
33. Teo S.K., Stirling D.I., Zeldis J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discovery Today 2005, 10:107-114.
34. Teo S.K., Resztak K.E., Scheffler M.A., Kook K.A., Zeldis J.B., Stirling D.I., et al. Thalidomide in the treatment of leprosy. Microbes and Infection 2002, 4:1193-1202.
35. Therapontos C., Erskine L., Gardner E.R., Figg W.D., Vargesson N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proceedings of the National Academy of Sciences United States of America 2009, 106:8573-8578.
36. Ito T., Handa H. Deciphering the mystery of thalidomide teratogenicity. Congenital Anomalies (Kyoto) 2012, 52:1-7.
37. Ito T., Ando H., Handa H. Teratogenic effects of thalidomide: molecular mechanisms. Cellular and Molecular Life Sciences 2011, 68:1569-1579.
38. Hansen J.M., Carney E.W., Harris C. Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro. Reproductive Toxicology 1999, 13:547-554.
39. Hansen J.M., Gong S.G., Philbert M., Harris C. Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide. Developmental Dynamics 2002, 225:186-194.
40. Hansen J.M., Harris C. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NF-kappaB pathway. Antioxidants & Redox Signaling 2004, 6:1-14.
41. Hansen J.M., Harris K.K., Philbert M.A., Harris C. Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb. Journal of Pharmacology and Experimental Therapeutics 2002, 300:768-776.
42. Parman T., Wiley M.J., Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Medicine 1999, 5:582-585.
43. Sauer H., Gunther J., Hescheler J., Wartenberg M. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. American Journal of Pathology 2000, 156:151-158.
44. Stratton K., Howe C., Battaglia F. Fetal Alcohol Syndrome: diagnosis, epidemiology, prevention and treatment 1996, National Academy Press, Washington DC, USA, p. 1-16.
45. Dreosti I.E. Micronutrients, superoxide and the fetus. Neurotoxicology 1987, 8:445-449.
46. Dreosti I.E., Manuel S.J., Buckley R.A. Superoxide dismutase (EC 1.15.1.1), manganese and the effect of ethanol in adult and foetal rats. British Journal of Nutrition 1982, 48:205-210.
47. Dreosti I.E., Patrick E.J. Zinc, ethanol, and lipid peroxidation in adult and fetal rats. Biological Trace Element Research 1987, 14:179-191.
48. Devi B.G., Henderson G.I., Frosto T.A., Schenker S. Effect of ethanol on rat fetal hepatocytes: studies on cell replication, lipid peroxidation and glutathione. Hepatology 1993, 18:648-659.
49. Henderson G.I., Devi B.G., Perez A., Schenker S. In utero ethanol exposure elicits oxidative stress in the rat fetus. Alcoholism Clinical and Experimental Research 1995, 19:714-720.
50. Woo G.H., Katayama K., Jung J.Y., Uetsuka K., Bak E.J., Nakayama H., et al. Hydroxyurea (HU)-induced apoptosis in the mouse fetal tissues. Histology and Histopathology 2003, 18:387-392.
51. Chaube S., Murphy M.L. The effects of hydroxyurea and related compounds on the rat fetus. Cancer Research 1966, 26:1448-1457.
52. Larouche G., Hales B.F. The impact of human superoxide dismutase 1 expression in a mouse model on the embryotoxicity of hydroxyurea. Birth Defects Research A Clinical and Molecular Teratology 2009, 85:800-807.
53. Desesso J.M., Scialli A.R., Goeringer G.C. D-mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. Teratology 1994, 49:248-259.
54. Yan J., Hales B.F. Activator protein-1 (AP-1) DNA binding activity is induced by hydroxyurea in organogenesis stage mouse embryos. Toxicological Sciences 2005, 85:1013-1023.
55. Amin-Zaki L., Elhassani S., Majeed M.A., Clarkson T.W., Doherty R.A., Greenwood M.R., et al. Perinatal methylmercury poisoning in Iraq. American Journal of Diseases of Children 1976, 130:1070-1076.
56. Harada M. Minamata disease: methylmercury poisoning in Japan caused by environmental pollution. Critical Reviews of Toxicology 1995, 25:1-24.
57. Gilbert S.G., Rice D.C., Burbacher T.M. Fixed interval/fixed ratio performance in adult monkeys exposed in utero to methylmercury. Neurotoxicology and Teratology 1996, 18:539-546.
58. Rice D.C. Effects of pre-plus postnatal exposure to methylmercury in the monkey on fixed interval and discrimination reversal performance. Neurotoxicology 1992, 13:443-452.
59. Rice D.C. Evidence for delayed neurotoxicity produced by methylmercury. Neurotoxicology 1996, 17:583-596.
60. Rice D.C., Gilbert S.G. Exposure to methyl mercury from birth to adulthood impairs high-frequency hearing in monkeys. Toxicology and Applied Pharmacology 1992, 115:6-10.
61. Thompson S.A., White C.C., Krejsa C.M., Eaton D.L., Kavanagh T.J. Modulation of glutathione and glutamate-L-cysteine ligase by methylmercury during mouse development. Toxicological Sciences 2000, 57:141-146.
62. Ornaghi F., Ferrini S., Prati M., Giavini E. The protective effects of N-acetyl-L-cysteine against methyl mercury embryotoxicity in mice. Fundamental and Applied Toxicology 1993, 20:437-445.
63. Fisher J.E., Potturi R.B., Collins M., Resnick E., Zimmerman E.F. Cocaine-induced embryonic cardiovascular disruption in mice. Teratology 1994, 49:182-191.
64. Johns J.M., Means M.J., Bass E.W., Means L.W., Zimmerman L.I., McMillen B.A. Prenatal exposure to cocaine: effects on aggression in Sprague-Dawley rats. Developmental Psychobiology 1994, 27:227-239.
65. Johns J.M., Noonan L.R., Zimmerman L.I., Li L., Pedersen C.A. Effects of chronic and acute cocaine treatment on the onset of maternal behavior and aggression in Sprague-Dawley rats. Behavioral Neuroscience 1994, 108:107-112.
66. Kashiwagi M., Chaoui R., Stallmach T., Hurlimann S., Lauper U., Hebisch G. Fetal bilateral renal agenesis, phocomelia, and single umbilical artery associated with cocaine abuse in early pregnancy. Birth Defects Research A Clinical and Molecular Teratology 2003, 67:951-952.
67. Rosenstein B.J., Wheeler J.S., Heid P.L. Congenital renal abnormalities in infants with in utero cocaine exposure. Journal of Urology 1990, 144:110-112.
68. Zimmerman E.F., Potturi R.B., Resnick E., Fisher J.E. Role of oxygen free radicals in cocaine-induced vascular disruption in mice. Teratology 1994, 49:192-201.
69. Lipton J.W., Gyawali S., Borys E.D., Koprich J.B., Ptaszny M., McGuire S.O. Prenatal cocaine administration increases glutathione and alpha-tocopherol oxidation in fetal rat brain. Brain Research Developmental Brain Research 2003, 147:77-84.
70. Ornoy A. Embryonic oxidative stress as a mechanism of teratogenesis with special emphasis on diabetic embryopathy. Reproductive Toxicology 2007, 24:31-41.
71. King G.L., Loeken M.R. Hyperglycemia-induced oxidative stress in diabetic complications. Histochemistry and Cell Biology 2004, 122:333-338.
72. Eriksson U.J., Borg L.A. Diabetes and embryonic malformations, Role of substrate-induced free-oxygen radical production for dysmorphogenesis in cultured rat embryos. Diabetes 1993, 42:411-419.
73. Cederberg J., Eriksson U.J. Antioxidative treatment of pregnant diabetic rats diminishes embryonic dysmorphogenesis. Birth Defects Research A Clinical and Molecular Teratology 2005, 73:498-505.
74. Cederberg J., Siman C.M., Eriksson U.J. Combined treatment with vitamin E and vitamin C decreases oxidative stress and improves fetal outcome in experimental diabetic pregnancy. Pediatric Research 2001, 49:755-762.
75. Schmahl H.J., Dencker L., Plum C., Chahoud I., Nau H. Stereoselective distribution of the teratogenic thalidomide analogue EM12 in the early embryo of marmoset monkey, Wistar rat and NMRI mouse. Archives of Toxicology 1996, 70:749-756.
76. Hansen J.M., Go Y.M., Jones D.P. Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annual Review of Pharmacology and Toxicology 2006, 46:215-234.
77. Watson W.H., Jones D.P. Oxidation of nuclear thioredoxin during oxidative stress. FEBS Letters 2003, 543:144-147.
78. Jones D.P. Redox sensing: orthogonal control in cell cycle and apoptosis signalling. Journal of Internal Medicine 2010, 268:432-448.
79. Hansen J.M., Zhang H., Jones D.P. Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-alpha-induced reactive oxygen species generation. NF-kappaB activation, and apoptosis. Toxicological Sciences 2006, 91:643-650.
80. Sundaresan M., Yu Z.X., Ferrans V.J., Sulciner D.J., Gutkind J.S., Irani K., et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochemical Journal 1996, 318(Pt 2):379-382.
81. Halvey P.J., Watson W.H., Hansen J.M., Go Y.M., Samali A., Jones D.P. Compartmental oxidation of thiol-disulphide redox couples during epidermal growth factor signalling. Biochemical Journal 2005, 386:215-219.
82. Hirota K., Murata M., Sachi Y., Nakamura H., Takeuchi J., Mori K., et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. Journal of Biological Chemistry 1999, 274:27891-27897.
83. Rhee S.G., Kang S.W., Chang T.S., Jeong W., Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 2001, 52:35-41.
84. Hansen J.M., Moriarty-Craige S., Jones D.P. Nuclear and cytoplasmic peroxiredoxin-1 differentially regulate NF-kappaB activities. Free Radical Biology and Medicine 2007, 43:282-288.
85. Hayes J.D., McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends in Biochemical Sciences 2009, 34:176-188.
86. Chan J.Y., Kwong M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochimica et Biophysica Acta 2000, 1517:19-26.
87. Kim Y.C., Masutani H., Yamaguchi Y., Itoh K., Yamamoto M., Yodoi J. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. Journal of Biological Chemistry 2001, 276:18399-18406.
88. Kim Y.J., Ahn J.Y., Liang P., Ip C., Zhang Y., Park Y.M. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Research 2007, 67:546-554.
89. Sakurai A., Nishimoto M., Himeno S., Imura N., Tsujimoto M., Kunimoto M., et al. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. Journal of Cell Physiology 2005, 203:529-537.
90. Sasaki H., Sato H., Kuriyama-Matsumura K., Sato K., Maebara K., Wang H., et al. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. Journal of Biological Chemistry 2002, 277:44765-44771.
91. Tanito M., Masutani H., Kim Y.C., Nishikawa M., Ohira A., Yodoi J. Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Investigative Ophthalmology & Visual Science 2005, 46:979-987.
92. He X., Ma Q. NRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and transcription activation. Molecular Pharmacology 2009, 76:1265-1278.
93. Bloom D., Dhakshinamoorthy S., Jaiswal A.K. Site-directed mutagenesis of cysteine to serine in the DNA binding region of Nrf2 decreases its capacity to upregulate antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene 2002, 21:2191-2200.
94. Hansen J.M., Watson W.H., Jones D.P. Compartmentation of Nrf-2 redox control: regulation of cytoplasmic activation by glutathione and DNA binding by thioredoxin-1. Toxicological Sciences 2004, 82:308-317.
95. Dong J., Sulik K.K., Chen S.Y. Nrf2-mediated transcriptional induction of antioxidant response in mouse embryos exposed to ethanol in vivo: implications for the prevention of fetal alcohol spectrum disorders. Antioxidants Redox Signaling 2008, 10:2023-2033.
96. Hutter D.E., Till B.G., Greene J.J. Redox state changes in density-dependent regulation of proliferation. Experimental Cell Research 1997, 232:435-438.
97. Hansen J.M., Klass M., Harris C., Csete M. A reducing redox environment promotes C2C12 myogenesis: implications for regeneration in aged muscle. Cell Biology International 2007, 31:546-553.
98. Imhoff B.R., Hansen J.M. Extracellular redox environments regulate adipocyte differentiation. Differentiation 2010, 80:31-39.
99. Kirlin W.G., Cai J., Thompson S.A., Diaz D., Kavanagh T.J., Jones D.P. Glutathione redox potential in response to differentiation and enzyme inducers. Free Radical Biology and Medicine 1999, 27:1208-1218.
100. Sullivan D.M., Levine R.L., Finkel T. Detection and affinity purification of oxidant-sensitive proteins using biotinylated glutathione ethyl ester. Methods in Enzymology 2002, 353:101-113.
101. Mackler B., Grace R., Duncan H.M. Studies of mitochondrial development during embryogenesis in the rat. Archives of Biochemistry and Biophysics 1971, 144:603-610.
102. Mackler B., Grace R., Haynes B., Bargman G.J., Shepard T.H. Studies of mitochondrial energy systems during embryogenesis in the rat. Archives of Biochemistry and Biophysics 1973, 158:662-666.
103. Shepard T.H., Muffley L.A., Smith L.T. Ultrastructural study of mitochondria and their cristae in embryonic rats and primate (N. nemistrina). Anatomical Record 1998, 252:383-392.
104. Fantel A.G., Person R.E., Tumbic R.W., Nguyen T.D., Mackler B. Studies of mitochondria in oxidative embryotoxicity. Teratology 1995, 52:190-195.
105. Wilson J.G. Mechanisms of teratogenesis. American Journal of Anatomy 1973, 136:129-131.
106. Kreipe U. [Abnormalities of internal organs in thalidomide embryopathy. A contribution to the determination of the sensitivity phase in thalidomide administration during early pregnancy]. Archiv fur Kinderheilkunde 1967, 176:33-61.
107. Lenz W. Epidemiology of congenital malformations. Annals of New York Academy of Sciences 1965, 123:228-236.
108. Lenz W., Knapp K. Thalidomide embryopathy. Archives of Environmental Health 1962, 5:100-105.
109. Meister A. Glutathione metabolism and its selective modification. Journal of Biological Chemistry 1988, 263:17205-17208.
110. Shi Z.Z., Osei-Frimpong J., Kala G., Kala S.V., Barrios R.J., Habib G.M., et al. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proceedings of the National Academy of Sciences United States of America 2000, 97:5101-5106.
111. Hiranruengchok R., Harris C. Glutathione oxidation and embryotoxicity elicited by diamide in the developing rat conceptus in vitro. Toxicology and Applied Pharmacology 1993, 120:62-71.
112. Liu J.N., Chan H.M., Kubow S. Oxidative stress status and development of late organogenesis stage rat whole embryos cultured from gestational days 13.5 to 14.5. Toxicological In Vitro 2007, 21:53-62.
113. Bellomo G., Palladini G., Vairetti M. Intranuclear distribution, function and fate of glutathione and glutathione-S-conjugate in living rat hepatocytes studied by fluorescence microscopy. Microscopy and Research Technique 1997, 36:243-252.
114. Cotgreave I.A. Analytical developments in the assay of intra- and extracellular GSH homeostasis: specific protein S-glutathionylation, cellular GSH and mixed disulphide compartmentalisation and interstitial GSH redox balance. Biofactors 2003, 17:269-277.
115. Voehringer D.W., McConkey D.J., McDonnell T.J., Brisbay S., Meyn R.E. Bcl-2 expression causes redistribution of glutathione to the nucleus. Proceedings of the National Academy of Sciences United States of America 1998, 95:2956-2960.
116. Matsui M., Oshima M., Oshima H., Takaku K., Maruyama T., Yodoi J., et al. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Developmental Biology 1996, 178:179-185.
117. Nonn L., Williams R.R., Erickson R.P., Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Molecular and Cellular Biology 2003, 23:916-922.
118. O'Hara M.F., Nibbio B.J., Craig R.C., Nemeth K.R., Charlap J.H., Knudsen T.B. Mitochondrial benzodiazepine receptors regulate oxygen homeostasis in the early mouse embryo. Reproductive Toxicology 2003, 17:365-375.
119. Hansen J.M. Thioredoxin redox status assessment during embryonic development: the redox Western. Methods in Molecular Biology 2012, 889:305-315.
120. Choe H., Hansen J.M., Harris C. Spatial and temporal ontogenies of glutathione peroxidase and glutathione disulfide reductase during development of the prenatal rat. Journal of Biochemical and Molecular Toxicology 2001, 15:197-206.
121. Hansen J.M., Choe H.S., Carney E.W., Harris C. Differential antioxidant enzyme activities and glutathione content between rat and rabbit conceptuses. Free Radical Biology and Medicine 2001, 30:1078-1088.
122. Harris C., Wang S.W., Lauchu J.J., Hansen J.M. Methanol metabolism and embryotoxicity in rat and mouse conceptuses: comparisons of alcohol dehydrogenase (ADH1), formaldehyde dehydrogenase (ADH3), and catalase. Reproductive Toxicology 2003, 17:349-357.
123. Hansen J.M., Lee E., Harris C. Spatial activities and induction of glutamate-cysteine ligase (GCL) in the postimplantation rat embryo and visceral yolk sac. Toxicological Sciences 2004, 81:371-378.
124. Harris C. Glutathione biosynthesis in the postimplantation rat conceptus in vitro. Toxicology and Applied Pharmacology 1993, 120:247-256.
125. Knobloch J., Reimann K., Klotz L.O., Ruther U. Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. Molecular Pharmacology 2008, 5:1138-1144.
126. de-Blanco E.J., Pandit B., Hu Z., Shi J., Lewis A., Li P.K. Inhibitors of NF-kappaB derived from thalidomide. Bioorganic Medicinal Chemistry Letters 2007, 17:6031-6035.
127. Li M., Sun W., Yang Y.P., Xu B., Yi W.Y., Ma Y.X., et al. In vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kappaB activation in HL-60 cells. Acta Pharmacologica Sinica 2009, 30:134-140.
128. Lv P., Luo H.S., Zhou X.P., Xiao Y.J., Paul S.C., Si X.M., et al. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Archives of Medical Research 2007, 38:15-27.
129. Bushdid P.B., Brantley D.M., Yull F.E., Blaeuer G.L., Hoffman L.H., Niswander L., et al. Inhibition of NF-kappaB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis. Nature 1998, 392:615-618.
130. Kanegae Y., Tavares A.T., Izpisua Belmonte J.C., Verma I.M. Role of Rel/NF-kappaB transcription factors during the outgrowth of the vertebrate limb. Nature 1998, 392:611-614.